Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGINTERVENTIONAL

L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)

Oral Antenatal L-citrulline Supplementation to Reduce Adverse Pregnancy Outcomes: a Two-arm, Randomized, Placebo-controlled Multi-site Trial in Kenya

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

There are few safe, effective, and affordable interventions to improve pregnancy outcomes in low resource settings where the highest rates of poor birth outcomes occur. L-citrulline is naturally found in many foods and is changed into another important amino acid, L-arginine, in the body. L-arginine is important for the growth of a healthy placenta and healthy baby. Adding L-citrulline to the diets of pregnant women may be an effective and affordable way to improve the health of their babies.The goal of the AGREE trial is to test whether a dietary supplement containing a common food component, an amino acid called L-citrulline, can help pregnant Kenyan women at risk of malaria have healthier pregnancies and healthier babies. 2,960 pregnant Kenyan women will be enrolled and randomly assigned to take either a twice daily dietary supplement containing L-citrulline or a placebo supplement without additional L-citrulline. Maternal participants will be seen every month until delivery and at weeks 1 and 6 after birth. Infants will also be followed up at ages 6, 12, 18, and 24 months. The primary outcome of the study is 'adverse pregnancy outcome', a composite of foetal loss (miscarriage or still birth), preterm birth, low birth weight, small for gestational age or neonatal mortality. The results of the AGREE trial could help to guide obstetric and public health policy and provide a sustainable solution that could be implemented at the community level.

Who May Be Eligible (Plain English)

Who May Qualify: - Pregnant women aged 16-40 years, - inclusive to 24 weeks gestational age as confirmed by ultrasound, - who have a viable singleton pregnancy, - are residents of the study area, - willing to adhere to scheduled and unscheduled study visit procedures, - willing to deliver in a study clinic or hospital Who Should NOT Join This Trial: - multiple pregnancies (i.e. twin/triplets); - pre-existing hypertension, renal disease and/or diabetes, or severe anaemia (Hb \< 5 g/dL); - HIV-positive or HIV status unknown; - malformations or nonviable pregnancy observed on enrolment ultrasound; - known allergy or contraindication to any of the study supplements including lactose intolerance or observing a lactose-free diet; - unable to give consent; or concurrent participation in any other clinical trial Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Pregnant women aged 16-40 years, * inclusive to 24 weeks gestational age as confirmed by ultrasound, * who have a viable singleton pregnancy, * are residents of the study area, * willing to adhere to scheduled and unscheduled study visit procedures, * willing to deliver in a study clinic or hospital Exclusion Criteria: * multiple pregnancies (i.e. twin/triplets); * pre-existing hypertension, renal disease and/or diabetes, or severe anaemia (Hb \< 5 g/dL); * HIV-positive or HIV status unknown; * malformations or nonviable pregnancy observed on enrolment ultrasound; * known allergy or contraindication to any of the study supplements including lactose intolerance or observing a lactose-free diet; * unable to give consent; or concurrent participation in any other clinical trial

Treatments Being Tested

DIETARY_SUPPLEMENT

L-citrulline

Twice daily 6.0 g sachet, each containing 5.00 g of quality-assured L-citrulline powder, 0.66 g maltodextrin and 0.30 g lactose anhydrous, 0.03 g citric acid, 0.01 g lemon flavour + antenatal standard of care with enhanced monitoring

Locations (1)

KEMRI Centre for Global Health Research
Kisumu, Kenya